Medtech Insight sat down with Think Surgical’s CFO Paul Weiner at the recent AAOS conference to discuss the roll-out of the next-generation TSolution One TKA robot and company plans.

The US agency issued a letter to providers in the wake of a study that found significantly higher complication rates in women implanted with Boston Scientific’s Watchman device.

The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.

The deal could nevertheless give Incyte a competitive edge, especially with combination potential between its JAK inhibitors and Syndax’s axatilimab.